Onco360® is a participating specialty pharmacy in the ZENBEXUS™ (iberdomide) limited dispense network
LOUISVILLE, Ky., Sept. 21, 2026 (GLOBE NEWSWIRE) -- Onco360®, the nation’s leading independent Specialty Pharmacy, has
Press Release Disclaimer: This is a press release distributed through the XPR Media network. It has not been independently verified by our newsroom.
LOUISVILLE, Ky., Sept. 21, 2026 (GLOBE NEWSWIRE) — Onco360®, the nation’s leading independent Specialty Pharmacy, has been selected as a participating pharmacy by Bristol-Myers Squibb for ZENBEXUS™ (iberdomide), indicated, in combination with daratumumab and hyaluronidase-fihj and dexamethasone, for the treatment of adult patients with multiple myeloma who have received at least 1 prior line of therapy including a proteasome inhibitor and an immunomodulatory agent.¹
“Onco360 is grateful for the opportunity to work with Bristol-Myers Squibb as a national specialty pharmacy provider for ZENBEXUS™,” said Benito Fernandez.
ZENBEXUS is a cereblon-modulating protein degrader that binds to cereblon, a substrate recognition component of an E3 ubiquitin ligase complex. ZENBEXUS engages cereblon and facilitates recruitment, ubiquitination, and proteasomal degradation of the transcription factors, Aiolos and Ikaros, resulting in anti‑tumor and immunomodulatory activity.¹ The prescribing information includes a boxed warning for embryo-fetal toxicity and serious venous and arterial thromboembolism. Because of the risk of embryo-fetal toxicity, ZENBEXUS is available only through a restricted distribution program called ZENBEXUS Risk Evaluation and Mitigation Strategy (REMS).
Efficacy was evaluated in EXCALIBER-RRMM (NCT04975997), a two-stage, randomized, multicenter, open-label trial in adults with relapsed or refractory multiple myeloma (RRMM) who had previously received one or two prior lines of therapy. Patients who had disease refractory to prior anti-CD38 monoclonal antibody therapy, or to prior bortezomib were excluded.² The major efficacy outcome measure was minimal residual disease (MRD)-negative complete response (CR) at any time. The primary efficacy population randomized to ZENBEXUS 1 mg in combination with Dd (n=207) or the comparator DVd arm (n=213) across stages 1 and stage 2. The MRD-negative CR rate at any time was 41% (95% CI: 34, 48) in the IberDd arm and 21% (95% CI: 15, 27) in the DVd arm.
The most common adverse reactions (≥20%) were upper respiratory tract infection, fatigue, musculoskeletal pain, pneumonia, diarrhea, motor dysfunction, rash, sleep disorder, hypogammaglobulinemia, COVID-19, and constipation.¹
Please read the full prescribing information for ZENBEXUS.
About Onco360 Oncology Pharmacy
Onco360 is the nation’s largest independent Oncology Pharmacy and clinical support services company. Onco360 was founded in 2003 to bring together the stakeholders involved in the cancer treatment process and serve the specialized needs of oncologists, patients, hospitals, cancer centers of excellence, manufacturers, health plans, and payers. It dispenses nationally through its network of URAC-, and ACHC-accredited Oncology Pharmacies. Onco360 is headquartered in Louisville, Kentucky, and is a flagship specialty pharmacy brand of PharMerica Corporation, a leading institutional pharmacy, specialty infusion, and hospital services company servicing healthcare facilities in the United States. For more information about Onco360, please visit Onco360.com.
Media Contact: Benito Fernandez, Chief Commercial Officer
Benito.fernandez@onco360.com
516-640-1332
References:
¹ZENBEXUS™ (iberdomide) [Package Insert]. Princeton, NJ. Bristol-Myers Squibb. 2026.
²Lonial S, et al. EXCALIBER-RRMM: a phase III trial of iberdomide, daratumumab, and dexamethasone in relapsed/refractory multiple myeloma. Future Oncol. 2025 Jun;21(14):1761-1769. doi: 10.1080/14796694.2025.2501920.
